Pfizer Inc. Continues Development Program for RemoxyĀ® (oxycodone … – PharmiWeb.com…

Pfizer Inc. (NYSE: PFE) announced today that having achieved technical milestones related to manufacturing it will continue the development program for Remoxy® (oxycodone) Extended-Release Capsules CII. Following guidance received from the U.S. Food and Drug Administration (FDA) earlier this year Pfizer will proceed with the additional clinical studies and other actions required to address the Complete Response Letter received in June (more…)

Pfizer Inc. Continues Development Program for Remoxy® (oxycodone … – Business Wire…

NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) announced today that, having achieved technical milestones related to manufacturing, it will continue the development program for Remoxy® (oxycodone) Extended-Release Capsules CII. Following guidance received from the U.S. Food and Drug Administration (FDA) earlier this year, Pfizer will proceed with the additional clinical studies and other actions required to address the Complete Response Letter received (more…)